AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

Research shows that Blacks may develop multiple sclerosis more often than previously thought. Additionally, the symptoms of the disease can progress more quickly or have a higher severity. Still, ...

Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Fingolimod is unable to slow disability progression or brain volume loss in patients with primary progressive multiple sclerosis (MS), show the findings of the INFORMS study. The findings, which are ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT ...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...